{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:48:16Z","timestamp":1776703696116,"version":"3.51.2"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T00:00:00Z","timestamp":1406592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eat Weight Disord"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40519-014-0139-y","type":"journal-article","created":{"date-parts":[[2014,7,28]],"date-time":"2014-07-28T08:55:35Z","timestamp":1406537735000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The therapy of insulin resistance in other diseases besides type 2 diabetes"],"prefix":"10.1007","volume":"19","author":[{"given":"Laura","family":"Pala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Barbaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Dicembrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Maria","family":"Rotella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,29]]},"reference":[{"key":"139_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","volume":"1","author":"PJ Randle","year":"1963","unstructured":"Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785\u2013789","journal-title":"Lancet"},{"key":"139_CR2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cell.2013.01.041","volume":"152","author":"AM Johnson","year":"2013","unstructured":"Johnson AM, Olefsky JM (2013) The origins and drivers of insulin resistance. Cell 152:673\u2013684","journal-title":"Cell"},{"key":"139_CR3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nature11705","volume":"491","author":"MG Myers Jr","year":"2012","unstructured":"Myers MG Jr, Olson DP (2012) Central nervous system control of metabolism. Nature 491:357\u2013363","journal-title":"Nature"},{"key":"139_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.nutr.24.012003.132155","volume":"25","author":"GM Reaven","year":"2005","unstructured":"Reaven GM (2005) The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 25:391\u2013406","journal-title":"Annu Rev Nutr"},{"key":"139_CR5","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1128\/MCB.00138-09","volume":"29","author":"S Guo","year":"2009","unstructured":"Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV, White MF (2009) The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29:5070\u20135083","journal-title":"Mol Cell Biol"},{"key":"139_CR6","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1073\/pnas.1000002107","volume":"107","author":"C Bouche","year":"2010","unstructured":"Bouche C, Lopez X, Fleischman A, Cypess AM, O\u2019Shea S, Stefanovski D, Bergman RN, Rogatsky E, Stein DT, Kahn CR et al (2010) Insulin enhances glucose-stimulated insulin secretion in healthy humans. PNAS 107:4770\u20134775","journal-title":"PNAS"},{"key":"139_CR7","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2337\/db13-0246","volume":"62","author":"CJ Rhodes","year":"2013","unstructured":"Rhodes CJ, White MF, Leahy JL, Kahn SE (2013) Direct autocrine action of insulin on b-cells: does it make physiological sense? Diabetes 62:2157\u20132163","journal-title":"Diabetes"},{"key":"139_CR8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1097-2765(00)80155-0","volume":"2","author":"JC Bruning","year":"1998","unstructured":"Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, Kahn CR (1998) A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2:559\u2013569","journal-title":"Mol Cell"},{"key":"139_CR9","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.2337\/db13-0095","volume":"62","author":"Y Qi","year":"2013","unstructured":"Qi Y, Xu Z, Zhu Q, Thomas C, Kumar R, Feng H, Dostal DE, White MF, Baker KM, Guo S (2013) Myocardial loss of IRS1 and IRS2 causes heart failure and Is controlled by p38a MAPK during insulin resistance. Diabetes 62:3887\u20133900","journal-title":"Diabetes"},{"key":"139_CR10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ecl.2008.06.001","volume":"37","author":"R Muniyappa","year":"2008","unstructured":"Muniyappa R, Iantorno M, Quon MJ (2008) An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am 37:685\u2013711","journal-title":"Endocrinol Metab Clin North Am"},{"key":"139_CR11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2010.06.003","volume":"142","author":"M Ferron","year":"2010","unstructured":"Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296\u2013308","journal-title":"Cell"},{"issue":"1","key":"139_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al (2009) American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1):193\u2013203","journal-title":"Diabetes Care"},{"issue":"2","key":"139_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-09-0733","volume":"162","author":"E Diamanti-Kandarakis","year":"2010","unstructured":"Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN (2010) Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162(2):193\u2013212","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"139_CR14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/157339906777950651","volume":"2","author":"CM Rotella","year":"2006","unstructured":"Rotella CM, Monami M, Mannucci E (2006) Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev 2(3):307\u2013315","journal-title":"Curr Diabetes Rev"},{"issue":"3","key":"139_CR15","first-page":"215","volume":"41","author":"T Tankova","year":"2003","unstructured":"Tankova T (2003) Current indications for metformin therapy. Rom J Intern Med 41(3):215\u2013225","journal-title":"Rom J Intern Med"},{"issue":"1","key":"139_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000323395","volume":"58","author":"S Muntoni","year":"2011","unstructured":"Muntoni S (2011) Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab 58(1):25\u201336","journal-title":"Ann Nutr Metab"},{"issue":"1","key":"139_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40272-013-0045-1","volume":"16","author":"DL Kendall","year":"2014","unstructured":"Kendall DL, Amin R, Clayton PE (2014) Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes. Paediatr Drugs 16(1):13\u201320","journal-title":"Paediatr Drugs"},{"issue":"5","key":"139_CR18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1159\/000345023","volume":"5","author":"C Bouza","year":"2012","unstructured":"Bouza C, L\u00f3pez-Cuadrado T, Gutierrez-Torres LF, Amate J (2012) Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts 5(5):753\u2013765","journal-title":"Obes Facts"},{"issue":"1","key":"139_CR19","first-page":"45","volume":"17","author":"KL Matson","year":"2012","unstructured":"Matson KL, Fallon RM (2012) Treatment of obesity in children and adolescents. J Pediatr Pharmacol Ther 17(1):45\u201357","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"9","key":"139_CR20","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2337\/dc09-0258","volume":"32","author":"MH Park","year":"2009","unstructured":"Park MH, Kinra S, Ward KJ, White B, Viner RM (2009) Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 32(9):1743\u20131745","journal-title":"Diabetes Care"},{"issue":"4","key":"139_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12519-010-0232-x","volume":"6","author":"H Rezvanian","year":"2010","unstructured":"Rezvanian H, Hashemipour M, Kelishadi R, Tavakoli N, Poursafa P (2010) A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr 6(4):317\u2013322","journal-title":"World J Pediatr"},{"issue":"2","key":"139_CR22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000353760","volume":"80","author":"C Brufani","year":"2013","unstructured":"Brufani C, Crin\u00f2 A, Fintini D, Patera PI, Cappa M, Manco M (2013) Systematic review of metformin use in obese nondiabetic children and adolescents. Horm Res Paediatr 80(2):78\u201385","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"139_CR23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11892-012-0263-x","volume":"12","author":"LH Kuller","year":"2012","unstructured":"Kuller LH (2012) Metformin use among individuals at risk for type 2 diabetes. Curr Diab Rep 12(3):265\u2013273","journal-title":"Curr Diab Rep"},{"issue":"2","key":"139_CR24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamapediatrics.2013.4200","volume":"168","author":"MS McDonagh","year":"2014","unstructured":"McDonagh MS, Selph S, Ozpinar A, Foley C (2014) Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr 168(2):178\u2013184","journal-title":"JAMA Pediatr"},{"issue":"1","key":"139_CR25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/jc.2012-2710","volume":"98","author":"J Wales","year":"2013","unstructured":"Wales J, Wright N, Clayton P, Hall C (2013) Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 98(1):322\u2013329","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"139_CR26","first-page":"269","volume":"41","author":"T Tankova","year":"2003","unstructured":"Tankova T, Dakovska L, Kirilov G, Koev D (2003) Metformin in the treatment of obesity in subjects with normal glucose tolerance. Rom J Intern Med 41(3):269\u2013275","journal-title":"Rom J Intern Med"},{"issue":"1\u20132","key":"139_CR27","first-page":"41","volume":"25","author":"ML Evia-Viscarra","year":"2012","unstructured":"Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jim\u00e9nez E, Mu\u00f1oz-Noriega N, Garc\u00eda-Morales LM, Lea\u00f1os-P\u00e9rez C, Figueroa-Barr\u00f3n M, S\u00e1nchez-Fierros D, Reyes-Garc\u00eda JG (2012) The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab 25(1\u20132):41\u201349","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"139_CR28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/HJH.0b013e328353e249","volume":"30","author":"H He","year":"2012","unstructured":"He H, Zhao Z, Chen J, Ni Y, Zhong J, Yan Z, Li Y, Liu D, Pletcher MJ, Zhu Z (2012) Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J Hypertens 30(7):1430\u20131439","journal-title":"J Hypertens"},{"key":"139_CR29","unstructured":"LeBlanc E, O\u2019Connor E, Whitlock EP, Patnode C, Kapka T (2011). Screening for and management of obesity and overweight in adults [Internet], Oct. Report. Agency for Healthcare Research and Quality (US), Rockville"},{"key":"139_CR30","first-page":"1","volume":"24","author":"JL Miller","year":"2013","unstructured":"Miller JL, Linville TD, Dykens EM (2013) Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J Pediatr Endocrinol Metab 24:1\u20137","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"6","key":"139_CR31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.plefa.2004.08.004","volume":"71","author":"Y Rodr\u00edguez","year":"2004","unstructured":"Rodr\u00edguez Y, Giri M, Feyen E, Christophe AB (2004) Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals. Prostaglandins Leukot Essent Fatty Acids 71(6):391\u2013397","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"139_CR32","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1194\/jlr.M027086","volume":"53","author":"M Fern\u00e1ndez-Galilea","year":"2012","unstructured":"Fern\u00e1ndez-Galilea M, P\u00e9rez-Matute P, Prieto-Hontoria PL, Martinez JA, Moreno-Aliaga MJ (2012) Effects of lipoic acid on lipolysis in 3T3-L1 adipocytes. J Lipid Res 53:2296\u20132306","journal-title":"J Lipid Res"},{"issue":"2","key":"139_CR33","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ijcard.2012.09.232","volume":"167","author":"Y Weili","year":"2013","unstructured":"Weili Y, Nong L, Xiaojuan H, Yongdi H, Weiguo Z, Qian W, Fugang W, Chenchen W, Xiaohu Z, Ruiwei X, Kai Y, Xiuhua D, Xiaoling W (2013) Effect of oral ALA supplementation on oxidative stress and insulin sensitivity among overweight\/obese adults: a double-blinded, randomized, controlled, cross-over intervention trial. Int J Cardiol 167(2):602\u2013603","journal-title":"Int J Cardiol"},{"key":"139_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bmj.293.6543.355","volume":"293","author":"J Adams","year":"1986","unstructured":"Adams J, Polson DW, Franks S (1986) Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 293:355\u2013359","journal-title":"Br Med J (Clin Res Ed)"},{"key":"139_CR35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.1999.00886.x","volume":"51","author":"KF Michelmore","year":"1999","unstructured":"Michelmore KF, Balen AH, Dunger DB, Vessey MP (1999) Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 51:779\u2013786","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"139_CR36","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1471-0528.2006.00990.x","volume":"113","author":"R Pasquali","year":"2006","unstructured":"Pasquali R, Gambineri A, Pagotto U (2006) The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113(10):1148\u20131597","journal-title":"BJOG"},{"key":"139_CR37","doi-asserted-by":"crossref","first-page":"14956","DOI":"10.1073\/pnas.95.25.14956","volume":"95","author":"RS Legro","year":"1998","unstructured":"Legro RS, Driscoll D, Straus JF III, Fox J, Dunaif A (1998) Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 95:14956\u201314960","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"139_CR38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bpobgyn.2004.05.002","volume":"18","author":"P Amato","year":"2004","unstructured":"Amato P, Simpson JL (2004) The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18(5):707\u2013718","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"6","key":"139_CR39","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1210\/jc.2005-1494","volume":"91","author":"JM Vink","year":"2006","unstructured":"Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI (2006) Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91(6):2100\u20132104","journal-title":"J Clin Endocrinol Metab"},{"key":"139_CR40","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","volume":"12","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E, Papavassiliou AG (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 12:324\u2013332","journal-title":"Trends Mol Med"},{"issue":"Suppl","key":"139_CR41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0002-9378(98)70240-6","volume":"179","author":"RS Legro","year":"1998","unstructured":"Legro RS (1998) Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 179(Suppl):101\u2013108","journal-title":"Am J Obstet Gynecol"},{"key":"139_CR42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/jcem-50-1-113","volume":"50","author":"GA Burghen","year":"1980","unstructured":"Burghen GA, Givens JR, Kitabchi AE (1980) Correlation with hyperandrogenism et hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113\u2013116","journal-title":"J Clin Endocrinol Metab"},{"key":"139_CR43","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2337\/diab.41.10.1257","volume":"41","author":"A Dunaif","year":"1992","unstructured":"Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257\u20131266","journal-title":"Diabetes"},{"key":"139_CR44","first-page":"942","volume":"81","author":"A Dunaif","year":"1996","unstructured":"Dunaif A, Finegood DT (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942\u2013947","journal-title":"J Clin Endocrinol Metab"},{"key":"139_CR45","doi-asserted-by":"crossref","unstructured":"Laven JSE, Mulders AGMGJ, van Santbrink, EJP, Eijkemans, MJC, Fauser, BCJM (2005). PCOS: backgrounds, evidence and problems in diagnosing the syndrome. In: Slager E, Fauser B, van Geijn H, Br\u00f6lmann H, Vervest H, editors. Gynaecology, obstetrics, and reproductive medicine in daily practice, Proceedings of the 15th congress of gynaecology, obstetrics and reproductive medicine. International congress series, vol 1279, pp 10\u201315","DOI":"10.1016\/j.ics.2005.01.002"},{"issue":"3","key":"139_CR46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.1993.tb02376.x","volume":"39","author":"S Robinson","year":"1993","unstructured":"Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R et al (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 39(3):351\u2013355","journal-title":"Clin Endocrinol (Oxf)"},{"key":"139_CR47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1380269","volume":"138","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A (1998) Therapeutic effects of metformin on insulin-resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138:269\u2013274","journal-title":"Eur J Endocrinol"},{"key":"139_CR48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJM199608293350902","volume":"335","author":"JE Nestler","year":"1996","unstructured":"Nestler JE, Jakubowicz DJ (1996) Decrease in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617\u2013623","journal-title":"N Engl J Med"},{"key":"139_CR49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0015-0282(01)01975-6","volume":"76","author":"GR Attia","year":"2001","unstructured":"Attia GR, Rainey WE, Carr BR (2001) Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 76:517\u2013524","journal-title":"Fertil Steril"},{"key":"139_CR50","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0015-0282(02)04346-7","volume":"78","author":"A Marca La","year":"2002","unstructured":"La Marca A, Morgante G, Palumbo M, Cianci A, Petraglia F, De Leo V (2002) Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril 78:1234\u20131239","journal-title":"Fertil Steril"},{"key":"139_CR51","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1095\/biolreprod.106.050831","volume":"75","author":"L Tosca","year":"2006","unstructured":"Tosca L, Solnais P, Ferre P, Foufelle F, Dupont J (2006) Metformin-induced stimulation of adenosine 5\u2032 monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod 75:342\u2013351","journal-title":"Biol Reprod"},{"key":"139_CR52","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","volume":"327","author":"JM Lord","year":"2003","unstructured":"Lord JM, Flight IH, Norman RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951\u2013953","journal-title":"BMJ"},{"key":"139_CR53","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/09513590601005847","volume":"22","author":"KI Chang","year":"2006","unstructured":"Chang KI, Sharma ST, Nestler JE (2006) Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? Gynecol Endocrinol 22:595\u2013604","journal-title":"Gynecol Endocrinol"},{"key":"139_CR54","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1210\/jc.2003-030424","volume":"88","author":"L Harborne","year":"2003","unstructured":"Harborne L, Fleming R, Lyall H, Satar N, Norman J (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 88:4116\u20134123","journal-title":"J Clin Endocrinol Metab"},{"key":"139_CR55","unstructured":"Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH (2010). Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev;1:CD003053"},{"key":"139_CR56","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4158\/EP.13.4.373","volume":"13","author":"ST Sharma","year":"2007","unstructured":"Sharma ST, Wickham EP III, Nestler JE (2007) Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. Endocr Pract 13:373\u2013379","journal-title":"Endocr Pract"},{"key":"139_CR57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1043-2760(02)00612-4","volume":"13","author":"RJ Norman","year":"2002","unstructured":"Norman RJ, Davies MJ, Lord J, Moran LJ (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Met 13:251\u2013257","journal-title":"Trends Endocrinol Met"},{"issue":"1","key":"139_CR58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","volume":"97","author":"BC Fauser","year":"2012","unstructured":"Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012) Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97(1):28\u201338","journal-title":"Fertil Steril"},{"key":"139_CR59","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2337\/diacare.13.3.244","volume":"13","author":"AR Saltiel","year":"1990","unstructured":"Saltiel AR (1990) Second messengers of insulin action. Diabetes Care 13:244\u2013256","journal-title":"Diabetes Care"},{"key":"139_CR60","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","volume":"340","author":"JE Nestler","year":"1999","unstructured":"Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G (1999) Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314\u20131320","journal-title":"N Engl J Med"},{"key":"139_CR61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09513590801893232","volume":"24","author":"AD Genazzani","year":"2008","unstructured":"Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM (2008) Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 24:139\u2013144","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"139_CR62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0015-0282(03)00571-5","volume":"80","author":"V Fenkci","year":"2003","unstructured":"Fenkci V, Fenkci S, Yilmazer M, Serteser M (2003) Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 80(1):123\u2013127","journal-title":"Fertil Steril"},{"key":"139_CR63","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.2337\/diab.45.12.1798","volume":"45","author":"DE Estrada","year":"1996","unstructured":"Estrada DE, Ewart HS, Tsakiridis T et al (1996) Stimulation of glucose uptake by the natural coenzyme \u03b1-lipoic acid\/thioctic acid. Participation of elements of the insulin signaling pathway. Diabetes 45:1798\u20131804","journal-title":"Diabetes"},{"issue":"2","key":"139_CR64","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/193229681000400218","volume":"4","author":"U Masharani","year":"2010","unstructured":"Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID (2010) Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol 4(2):359\u2013364","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"139_CR65","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbrc.2005.05.035","volume":"332","author":"WJ Lee","year":"2005","unstructured":"Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, Kim MS, Kim SW, Lee KU, Park JY (2005) Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 332(3):885\u2013891","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"139_CR66","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S1499-3872(13)60092-2","volume":"12","author":"M Olaywi","year":"2013","unstructured":"Olaywi M, Bhatia T, Anand S, Singhal S (2013) Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 12(6):584\u2013588","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"139_CR67","doi-asserted-by":"crossref","first-page":"716404","DOI":"10.1155\/2012\/716404","volume":"2012","author":"A Mazza","year":"2012","unstructured":"Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A (2012) The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012:716404","journal-title":"Exp Diabetes Res."},{"issue":"9","key":"139_CR68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jnutbio.2007.10.001","volume":"19","author":"CL Gentile","year":"2008","unstructured":"Gentile CL, Pagliassotti MJ (2008) The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 19(9):567\u2013576","journal-title":"J Nutr Biochem"},{"issue":"8","key":"139_CR69","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2337\/db11-0231","volume":"60","author":"N Stefan","year":"2011","unstructured":"Stefan N, H\u00e4ring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60(8):2011\u20132017","journal-title":"Diabetes"},{"issue":"2","key":"139_CR70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cld.2012.03.005","volume":"16","author":"AH Paredes","year":"2012","unstructured":"Paredes AH, Torres DM, Harrison SA (2012) Nonalcoholic fatty liver disease. Clin Liver Dis 16(2):397\u2013419","journal-title":"Clin Liver Dis"},{"issue":"11","key":"139_CR71","doi-asserted-by":"crossref","first-page":"22933","DOI":"10.3390\/ijms141122933","volume":"14","author":"B Fruci","year":"2013","unstructured":"Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A (2013) Nonalcoholic fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 14(11):22933\u201322966","journal-title":"Int J Mol Sci"},{"issue":"12","key":"139_CR72","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/ajg.2010.363","volume":"105","author":"PR Kenny","year":"2010","unstructured":"Kenny PR, Brady DE, Torres DM, Ragozzino L, Chalasani N, Harrison SA (2010) Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 105(12):2707\u20132709","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"139_CR73","first-page":"507","volume":"21","author":"M Kohjima","year":"2008","unstructured":"Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, Nakamuta M (2008) SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21(4):507\u2013511","journal-title":"Int J Mol Med"},{"issue":"1","key":"139_CR74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3892\/ijmm.2013.1560","volume":"33","author":"F Liu","year":"2014","unstructured":"Liu F, Wang C, Zhang L, Xu Y, Jang L, Gu Y, Cao X, Zhao X, Ye J, Li Q (2014) Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein. Int J Mol Med 33(1):51\u201358","journal-title":"Int J Mol Med"},{"issue":"9285","key":"139_CR75","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","volume":"358","author":"G Marchesini","year":"2001","unstructured":"Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358(9285):893\u2013894","journal-title":"Lancet"},{"issue":"5","key":"139_CR76","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","volume":"19","author":"A Uygun","year":"2004","unstructured":"Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19(5):537\u2013544","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"139_CR77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","volume":"20","author":"S Nair","year":"2004","unstructured":"Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP (2004) Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20(1):23\u201328","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"139_CR78","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","volume":"100","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100(5):1082\u20131090","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"139_CR79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1381\/0960892053723268","volume":"15","author":"DJ Janiec","year":"2005","unstructured":"Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H (2005) Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 15(4):497\u2013501","journal-title":"Obes Surg"},{"issue":"4","key":"139_CR80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1665-2681(19)31902-7","volume":"6","author":"A Duseja","year":"2007","unstructured":"Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A (2007) Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 6(4):222\u2013226","journal-title":"Ann Hepatol"},{"issue":"2","key":"139_CR81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1872-034X.2007.00215.x","volume":"38","author":"CP Oliveira De","year":"2008","unstructured":"De Oliveira CP, Stefano JT, De Siqueira ER, Silva LS, De Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ (2008) Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 38(2):159\u2013165","journal-title":"Hepatol Res"},{"issue":"2","key":"139_CR82","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","volume":"28","author":"R Idilman","year":"2008","unstructured":"Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R, Uysal AR, Ozden A (2008) Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28(2):200\u2013208","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"139_CR83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","volume":"29","author":"R Loomba","year":"2009","unstructured":"Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH (2009) Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29(2):172\u2013182","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"139_CR84","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/ijo.2010.40","volume":"34","author":"GA Garinis","year":"2010","unstructured":"Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A (2010) Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 34(8):1255\u20131264","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"139_CR85","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","volume":"44","author":"JW Haukeland","year":"2009","unstructured":"Haukeland JW, Konopski Z, Eggesb\u00f8 HB, von Volkmann HL, Raschpichler G, Bj\u00f8ro K, Haaland T, L\u00f8berg EM, Birkeland K (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44(7):853\u2013860","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"139_CR86","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","volume":"22","author":"Z Omer","year":"2010","unstructured":"Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U (2010) Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 22(1):18\u201323","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"139_CR87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00592-008-0067-2","volume":"46","author":"A Nar","year":"2009","unstructured":"Nar A, Gedik O (2009) The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46(2):113\u2013118","journal-title":"Acta Diabetol"},{"issue":"3","key":"139_CR88","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756283X09105462","volume":"2","author":"WW Shields","year":"2009","unstructured":"Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ (2009) The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2(3):157\u2013163","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"139_CR89","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cct.2009.09.001","volume":"31","author":"JE Lavine","year":"2010","unstructured":"Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J, Nonalcoholic Steatohepatitis Clinical Research Network Research Group (2010) Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 31(1):62\u201370","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"139_CR90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12543","volume":"39","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L (2014) Systematic review with meta-analysis: non-alcoholic steatohepatitis\u2014a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 39(1):3\u201314","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"139_CR91","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005\u20132023","journal-title":"Hepatology"},{"issue":"1","key":"139_CR92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","volume":"35","author":"E Boettcher","year":"2012","unstructured":"Boettcher E, Csako G, Pucino F, Wesley R, Loomba R (2012) Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 35(1):66\u201375","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"139_CR93","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0929-6646(09)60202-3","volume":"105","author":"CH Wang","year":"2006","unstructured":"Wang CH, Leung CH, Liu SC, Chung CH (2006) Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease. J Formos Med Assoc 105(9):743\u2013752","journal-title":"J Formos Med Assoc"},{"issue":"9","key":"139_CR94","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s10620-006-9145-x","volume":"52","author":"F Aky\u00fcz","year":"2007","unstructured":"Aky\u00fcz F, Demir K, Ozdil S, Aksoy N, Poturo\u011flu S, Ibri\u015fim D, Kaymako\u011flu S, Be\u015fi\u015fik F, Bozta\u015f G, Cakalo\u011flu Y, Mungan Z, Cevikba\u015f U, Okten A (2007) The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci 52(9):2359\u20132367","journal-title":"Dig Dis Sci"},{"issue":"22","key":"139_CR95","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297\u20132307","journal-title":"N Engl J Med"},{"issue":"4","key":"139_CR96","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","volume":"135","author":"GP Aithal","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135(4):1176\u20131184","journal-title":"Gastroenterology"},{"issue":"6","key":"139_CR97","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"18","key":"139_CR98","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, NASH CRN (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18):1675\u20131685","journal-title":"N Engl J Med"},{"key":"139_CR99","unstructured":"Dohahue S, Marathe P, Guld T., Meeker J. (2002) The pharmacokinetics and pharmacodynamics of extended-release metformin tablets vs immediate-release metformin in subjects with Type 2 diabetes. Diabetes 51 (suppl. 2): A468"},{"key":"139_CR100","doi-asserted-by":"crossref","unstructured":"Pala L, Rotella CM (2014) The slower the better. JEI 37:497\u2013498","DOI":"10.1007\/s40618-014-0065-x"},{"issue":"2","key":"139_CR101","first-page":"116","volume":"164","author":"DM Wilson","year":"2010","unstructured":"Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH, Osganian SV, Feldman HA, Glaser Pediatric Research Network Obesity Study Group (2010) Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 164(2):116\u2013123","journal-title":"Arch Pediatr Adolesc Med."}],"container-title":["Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40519-014-0139-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40519-014-0139-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40519-014-0139-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T13:29:34Z","timestamp":1717162174000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40519-014-0139-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,29]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1007\/s40519-014-0139-y","relation":{},"ISSN":["1124-4909","1590-1262"],"issn-type":[{"value":"1124-4909","type":"print"},{"value":"1590-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,29]]}}}